Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | P4HB | P07237 | 2/20 | 0.43 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475844 | 0.83 | ALDH1A1 (0.49) | ACHEALDH1A1L3MBTL1HSD17B10KDM4E | |
| SCHEMBL25384511 | 0.81 | ACHE (0.47) | ACHEALDH1A1L3MBTL1HSD17B10KDM4E | |
| SCHEMBL2950477 | 0.81 | ALDH1A1 (0.47) | ACHEALDH1A1L3MBTL1HSD17B10KDM4E | |
| SCHEMBL13163095 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TSHR | |
| SCHEMBL3311700 | 0.78 | MAPT (0.55) | ALDH1A1KDM4ESMN1; SMN2KMT2AHIF1A | |
| SCHEMBL13638740 | 0.76 | LTA4H (0.38) | ACHEALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2950474 | 0.76 | KDM4E (0.53) | ALDH1A1L3MBTL1KDM4EMEN1KMT2A | |
| SCHEMBL8983621 | 0.75 | ALDH1A1 (0.65) | ACHEALDH1A1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL17696098 | 0.75 | OGA (0.42) | — | |
| SCHEMBL263756 | 0.75 | LTA4H (0.49) | ACHEALDH1A1SMN1; SMN2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | ACHE 1111/4885ALDH1A1 238/4885L3MBTL1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.